Hayek Kallen Investment Management increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 2.9% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 17,941 shares of the company’s stock after buying an additional 508 shares during the quarter. Hayek Kallen Investment Management’s holdings in Merck & Co., Inc. were worth $1,510,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Titan Capital Management LLC CA purchased a new position in Merck & Co., Inc. in the second quarter worth about $25,000. LFA Lugano Financial Advisors SA boosted its position in Merck & Co., Inc. by 250.0% in the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after purchasing an additional 225 shares during the last quarter. JJJ Advisors Inc. purchased a new position in Merck & Co., Inc. in the second quarter worth about $27,000. Cumberland Partners Ltd purchased a new position in Merck & Co., Inc. in the second quarter worth about $40,000. Finally, Fusion Family Wealth LLC boosted its position in Merck & Co., Inc. by 268.2% in the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after purchasing an additional 354 shares during the last quarter. Institutional investors own 74.95% of the company’s stock.
Shares of MRK stock traded up $0.71 during trading hours on Friday, reaching $83.59. 6,053,527 shares of the company traded hands, compared to its average volume of 10,105,755. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $87.35. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. The company has a market cap of $212.31 billion, a P/E ratio of 19.26, a P/E/G ratio of 1.80 and a beta of 0.54. The firm has a 50-day moving average price of $84.01 and a 200 day moving average price of $82.77.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The firm had revenue of $12.40 billion for the quarter, compared to analysts’ expectations of $11.59 billion. During the same period in the previous year, the firm earned $1.19 EPS. The business’s quarterly revenue was up 14.9% on a year-over-year basis. Sell-side analysts predict that Merck & Co., Inc. will post 5.16 EPS for the current year.
Several research analysts have issued reports on the company. Societe Generale set a $105.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Mizuho raised their target price on Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. ValuEngine cut Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. set a $96.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Thursday, October 10th. Finally, Leerink Swann assumed coverage on Merck & Co., Inc. in a research report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company. Merck & Co., Inc. has an average rating of “Buy” and an average target price of $95.13.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Story: Mutual Funds
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.